Table 2.

Radiation dosing and toxicity outcomes compared among the present study and previous studies that supplemented external beam radiation therapy (EBRT) with simultaneous integrated boost (SIB) to the dominant intraprostatic lesion (DIL)

	Fonteyne et al (2008) [10]	Schild et al (2014) [7]	Ippolito et al (2015) [12]	FLAME trial (2020) [14]	Present study
Prostate dose (boost dose)	78 Gy (81–82 Gy)	75.6–77.4 Gy (83 Gy)	72 Gy (80 Gy)	77 Gy (95 Gy)	78 Gy/60 Gy (87.75 Gy/70 Gy)
No. patients	230	78	40	571	45
Median F/U	9 months	36 months	19 months	72 months	20 months
Acute GU toxicity	Grade 2 = 41% Grade 3 = 7% No grade 4	Grade 2 = 53% No grade 3–4	Grade 2 = 30% Grade 3 = 2.5% No grade 4	= grade 2 = 42.3%* (Report in 2007) [23]	Grade 2 = 26.7% Grade 3 = 2.2% No grade 4
Acute GI toxicity	Grade 2 = 11% No grade 3–4	Grade 2 = 19% No grade 3–4	Grade 2 = 15% Grade 3 = 5% No grade 4	≥ grade 2 = 14.8%* (Report in 2007) [23]	Grade 2 = 6.7% Grade 3 = 2.2% No grade 4
Late GU toxicity	N/A	Grade 2 = 26% Grade 3 = 3% No grade 4	Grade 2 = 5% Grade 3 = N/A Grade 4 = 2.5%	≥ grade 2 = 28%	Grade 2 = 8.9% No grade 3–4
Late GI toxicity	N/A	Grade 2 = 4% Grade 3 = 0% No grade 4	Grade 2 = 2.5% Grade 3 = 2.5% No grade 4	≥ grade 2 = 13%	Grade 2 = 2.2% No grade 3–4

GU — genitourinary; GI — gastrointestinal